#1 Clinical Trials Search in Europe

Etravirine

Etravirine, an antiretroviral medication, has been the subject of several clinical trials investigating its efficacy, safety, and potential applications. These studies have primarily focused on its use in treating HIV infections, but have also explored its effects on other conditions. The trials have examined various aspects of etravirine, including its dosing regimens, pharmacokinetics, and impact on patients’ quality of life.

Table of Contents

What is Etravirine?

Etravirine, also known by its brand name Intelence or research code TMC125, is an antiretroviral medication used to treat Human Immunodeficiency Virus (HIV) infections[1]. It belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which work by blocking a specific enzyme that HIV needs to multiply[2].

How Etravirine Works

Etravirine works by inhibiting the action of an enzyme called reverse transcriptase, which is essential for HIV to replicate. By doing so, it helps to reduce the amount of HIV in the body, allowing the immune system to function better and decreasing the risk of HIV-related complications[2]. Etravirine has shown high activity against wild-type HIV-1 (the most common type of HIV) and even against HIV strains that have become resistant to other non-nucleoside agents[3].

Conditions Treated with Etravirine

Etravirine is primarily used to treat:

  • HIV-1 Infections: It is used in combination with other antiretroviral agents to treat HIV-1 infected patients who have experience with antiretroviral treatment[1][2].
  • Treatment-Experienced Patients: Etravirine is particularly useful for patients who have developed resistance to other HIV medications[3].

Dosage and Administration

Etravirine is typically administered as follows:

  • Adult Dosage: The standard dose for adults is 200 mg (two 100 mg tablets) taken twice daily after a meal[1].
  • Pediatric Dosage: For children and adolescents (6 years to less than 18 years old), the dose is based on body weight, ranging from 100 mg to 200 mg twice daily[1].
  • Administration: Etravirine tablets should be swallowed whole with a liquid. For patients who have difficulty swallowing, the tablets can be dispersed in a glass of water[4].

Side Effects and Safety

Like all medications, Etravirine can cause side effects. Common side effects include:

  • Skin rash: This is usually mild to moderate and often resolves on its own[3].
  • Gastrointestinal issues: Such as nausea, vomiting, and diarrhea[3].
  • Headache and fatigue[3].

Importantly, Etravirine has shown lower rates of central nervous system (CNS) side effects compared to some other HIV medications like Efavirenz. This includes fewer instances of dizziness, abnormal dreams, and sleep disturbances[5].

Drug Interactions

Etravirine can interact with other medications. It’s important to inform your healthcare provider about all medications you’re taking. Some notable interactions include:

  • Other HIV medications: Etravirine may interact with certain protease inhibitors and other antiretroviral drugs[6].
  • Hepatitis C medications: There may be interactions with drugs like Boceprevir[6].

Use in Special Populations

Etravirine use in special populations:

  • Pregnancy: Animal studies have shown a low risk of birth defects, but more research is needed in humans[3].
  • Children: Etravirine is approved for use in children 2 years of age and older[1].
  • Elderly: Limited information is available on the use of Etravirine in patients over 65 years old.

Ongoing Research and Future Applications

Research on Etravirine is ongoing, exploring its potential in various areas:

  • Once-daily dosing: Studies are investigating the efficacy of Etravirine when given once daily instead of twice daily[7].
  • Treatment of other conditions: Etravirine is being studied for potential use in treating Friedreich’s Ataxia, a rare genetic disorder affecting the nervous system[8].
  • Improved formulations: Research is being conducted on different tablet formulations to improve swallowability and patient comfort[4].
Aspect Details
Primary Use Treatment of HIV-1 infections
Mechanism of Action Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Dosing Typically 200mg twice daily, with some trials exploring 400mg once daily
Efficacy Effective in reducing viral load and increasing CD4+ count in HIV patients
Side Effects Generally well-tolerated; fewer neuropsychiatric side effects compared to efavirenz
Special Populations Studied in treatment-experienced patients and children/adolescents
Other Applications Investigated for potential use in Friedreich Ataxia
Patient Preference Some studies suggest improved sleep quality and fewer CNS side effects compared to efavirenz

FAQ

  • What is etravirine and how does it work? Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infections. It works by blocking the action of reverse transcriptase, an enzyme that HIV needs to multiply.
  • What are the common side effects of etravirine? Common side effects of etravirine may include rash, nausea, headache, and fatigue. However, it generally has fewer neuropsychiatric side effects compared to some other HIV medications like efavirenz.
  • Can etravirine be taken once daily? Some clinical trials have explored the possibility of once-daily dosing of etravirine. However, the standard dosing is typically twice daily. Always follow your healthcare provider's instructions.
  • Is etravirine being studied for conditions other than HIV? Yes, etravirine has been studied in clinical trials for other conditions. For example, one trial explored its potential use in patients with Friedreich Ataxia, a rare genetic disorder.
  • How does etravirine compare to other HIV medications in terms of side effects? Clinical trials have shown that etravirine generally has fewer central nervous system side effects compared to some other HIV medications, particularly efavirenz. This can lead to improved sleep quality and fewer neuropsychiatric symptoms for some patients.

Ongoing Clinical Trials on Etravirine

  • Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Germany Ireland The Netherlands Spain

Glossary

  • Antiretroviral: A type of medication used to treat HIV infections by preventing the virus from multiplying.
  • CD4+ count: A measure of the number of CD4 T lymphocytes (T cells) in the blood, which is an indicator of immune system health in HIV patients.
  • Efavirenz: Another type of non-nucleoside reverse transcriptase inhibitor used to treat HIV, often compared to etravirine in clinical trials.
  • Friedreich Ataxia: A rare genetic disorder affecting the nervous system and heart, which has been studied in relation to etravirine treatment.
  • HIV-1: Human Immunodeficiency Virus type 1, the most common type of HIV that causes AIDS.
  • Non-nucleoside reverse transcriptase inhibitor (NNRTI): A class of antiretroviral drugs that bind to and disable reverse transcriptase, an enzyme crucial for HIV replication.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Viral load: The amount of HIV in a person's blood, usually measured as HIV RNA copies per milliliter.
  • Virologic failure: When antiretroviral therapy fails to suppress and sustain a person's viral load to less than 200 copies/mL.
  • DEXA scan: Dual-energy X-ray absorptiometry, a type of scan used to measure bone density and body composition.

References

  1. https://clinicaltrials.gov/study/NCT00980538
  2. https://clinicaltrials.gov/study/NCT01422330
  3. https://clinicaltrials.gov/study/NCT00792324
  4. https://clinicaltrials.gov/study/NCT01090648
  5. https://clinicaltrials.gov/study/NCT00792584
  6. https://clinicaltrials.gov/study/NCT01427504
  7. https://clinicaltrials.gov/study/NCT00959894
  8. https://clinicaltrials.gov/study/NCT04273165